| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | 0.16 | 8e-05 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.17 | 9e-05 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0001 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.17 | 0.0001 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0001 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0001 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0001 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.26 | 0.0001 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.27 | 0.0001 |